Skip to main content
An official website of the United States government
Email

Pre-Application Webinars for the Human Tumor Atlas Network

Pre-Application Webinar; RFA-CA-23-039 & RFA-CA-23-040; Human Tumor Atlas Network (HTAN): Human Tumor Atlas (HTA) & Pre-Cancer Atlas (PCA) Research Centers (U01 Clinical Trial Not Allowed); HTAN banner with the image of a tumor; Thursday, November 9th; 2:00-3:00 pm ET & 3:00-4:00 pm ET

On November 9. 2023 from 2:00 - 4:00 pm ET, NCI  held back-to-back pre-application webinars on two recently published Notices of Funding Opportunities (NOFOs) for the Human Tumor Atlas Network (HTAN). The webinars provided an overview of the HTAN program and addressed frequently asked questions related to the NOFOs.

HTAN Funding Opportunities in the Webinars 

  • RFA-CA-23-039: Human Tumor Atlas (HTA) Research Centers (U01 Clinical Trial Not Allowed)
  • RFA-CA-23-040: Pre-Cancer Atlas (PCA) Research Centers (U01 Clinical Trial Not Allowed)

Materials from the Pre-Application Webinars

  • Human Tumor Atlas (HTA) Research Centers Webinar: slides and recording 
  • Pre-Cancer Atlas (PCA) Research Centers Webinar: slides and recording 
  • NOT-CA-23-095: Notice of Pre-Application Webinar for RFA-CA-23-039 and RFA-CA-23-040 for the National Cancer Institute "Human Tumor Atlas Network (HTAN)" Program

Frequently Asked Questions (FAQs) from the Pre-Application Webinars

FAQs related to the HTAN program and NOFOs can be found in this document. 

Contacts for the HTAN NOFOs and Pre-Application Webinars

For additional information about HTAN funding opportunities, please contact Dr. Sharmistha Ghosh-Janjigian or Dr. Indu Kohaar.

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Pre-Application Webinars for the Human Tumor Atlas Network was originally published by the National Cancer Institute.”

Email